ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2013, Pages 388-394

  Zismanov, Victoria ^a,b   Drucker, Liat ^a,b   Gottfried, Maya ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

17 DMAG; ER homeostasis; ER stress; Lung cancer; PTACH; Unfolded protein response

Indexed keywords

17DMAG; ALVESPIMYCIN; HISTONE DEACETYLASE INHIBITOR; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVITY; CELL DEATH; CELL LINE; CELL MIGRATION; CELL MOTILITY; DOSE RESPONSE; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CHAPERONINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HISTONE DEACETYLASE INHIBITORS; HOMEOSTASIS; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION;

EID: 84875937125     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.02.004     Document Type: Article

References (33)

1. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
2. Sun S., Schiller J.H., Spinola M., Minna J.D. New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117:2740-2750.
3. Rajan A., Gutierrez M., Giaccone G. Newer opportunities in systemic therapy of lung cancer. Ann Oncol 2008, 19(Suppl. 7):vii31-vii37.
4. Jorgensen E., Stinson A., Shan L., Yang J., Gietl D., Albino A.P. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer 2008, 8:229.
5. Wlodkowic D., Skommer J., McGuinness D., Hillier C., Darzynkiewicz Z. ER-Golgi network-a future target for anti-cancer therapy. Leuk Res 2009, 33:1440-1447.
6. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009, 15:9-14.
7. Kakihana M., Ohira T., Chan D., Webster R.B., Kato H., Drabkin H.A., et al. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 2009, 4:1455-1465.
8. Li D., Marchenko N.D., Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011, 18:1904-1913.
9. Shimamura T., Shapiro G.I. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008, 3:S152-S159.
10. Wang G., Ye Y., Yang X., Liao H., Zhao C., Liang S. Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One 2011, 6:e14573.
11. Gridelli C., Rossi A., Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008, 68:29-36.
12. Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H., Dosik H., et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973, 51:1417-1423.
13. Giaccone G., Battey J., Gazdar A.F., Oie H., Draoui M., Moody T.W. Neuromedin B is present in lung cancer cell lines. Cancer Res 1992, 52:2732s-2736s.
14. Banks-Schlegel S.P., Gazdar A.F., Harris C.C. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res 1985, 45:1187-1197.
15. Kobayashi N., Toyooka S., Soh J., Yamamoto H., Dote H., Kawasaki K., et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 2011.
16. Suzuki T., Nagano Y., Kouketsu A., Matsuura A., Maruyama S., Kurotaki M., et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 2005, 48:1019-1032.
17. Kawabe M., Mandic M., Taylor J.L., Vasquez C.A., Wesa A.K., Neckers L.M., et al. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res 2009, 69:6995-7003.
18. Rao R., Lee P., Fiskus W., Yang Y., Joshi R., Wang Y., et al. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther 2009, 8:1273-1280.
19. Koll T.T., Feis S.S., Wright M.H., Teniola M.M., Richardson M.M., Robles A.I., et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008, 7:1985-1992.
20. Zismanov V., Lishner M., Tartakover-Matalon S., Radnay J., Shapiro H., Drucker L. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer 2009, 101:1402-1409.
21. Su D.F., Xu L.P., Miao C.Y., Xie H.H., Shen F.M., Jiang Y.Y. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 2004, 25:148-151.
22. Li X., Zhang K., Li Z. Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol 2011, 4:8.
23. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007, 21:2172-2181.
24. Kaiser M., Lamottke B., Mieth M., Jensen M.R., Quadt C., Garcia-Echeverria C., et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010, 84:337-344.
25. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
26. Nguyen A., Su L., Campbell B., Poulin N.M., Nielsen T.O. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009, 2009:794901.
27. Marcinak S.J., Ron D. The unfolded protein response in lung disease. Proc Am Thorac Soc 2010, 7:356-362.
28. Zhao Y., Zhu C., Li X., Zhang Z., Yuan Y., Ni Y., et al. Asterosaponin 1 induces endoplasmic reticulum stress-associated apoptosis in A549 human lung cancer cells. Oncol Rep 2011, 26:919-924.
29. Gorman A.M., Healy S.J., Jager R., Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther 2012, 134:306-316.
30. Wang Y., Xiao J., Zhou H., Yang S., Wu X., Jiang C., et al. A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem 2011, 54:3768-3778.
31. Xie Q., Gao C.F., Shinomiya N., Sausville E., Hay R., Gustafson M., et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005, 24:3697-3707.
32. Hudak L., Tezeeh P., Wedel S., Makarevic J., Juengel E., Tsaur I., et al. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 2012, [Epub ahead of print].
33. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011, 9:18.